Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Stone who wrote (3834)	8/7/1998 1:24:00 PM
From: Elllk	Read Replies (2) \| Respond to of 4342

Harold My guess was that since PRLN had gone up for 2 days, while the market took an enormous hit, the size of the bid/ask in the past few days has been fairly accurate. If so it has been reflecting someone wanting to get out, maybe in favor of blue chips, cash, bonds, etc., and maybe because of losses elsewhere in the big sell off. You'll notice a lot of maybes here. The bid/ask, of course, is not beyond manipulation and shouldn't be taken too seriously. Level II access, for instance, has become such a hot thing that I am sure that gets manipulated all the time. My sense with PRLN is that most of us left in it are in for the longer run, especially with all the new developments with the new management in charge. It also seems to me that the de facto float has shrunk and that an MM would be wasting time trying to shake out much here. On other hand, what else do MMs have to do? Plus when a stock has been below $1 for a long time there is tremendous resistence at that level and PRLN has retreated from such bounces repeatedly in the past so who is to say some shaking out can't be done around the $1 area even though my opinion is that the $1 barrier is now gone, especially with news in several areas imminent. So Harold, I hope maybe this maybe makes my interpretation almost "perfectly clear" about this issue, maybe. On another issue, I did notice that some new PRLN studies are going to be done using, thats right, *MICE!!* So our company continues to show its forward looking wisdom, in this case by taking paul's cleverly disguised advice. Larry

To: Harold Stone who wrote (3834)	8/12/1998 4:51:00 PM
From: Harold Stone	Read Replies (1) \| Respond to of 4342

Fellow Threaders, NEWS PR NewsWire Paracelsian Announces Biomar Investment and Warrant Actions ITHACA, N.Y., Aug. 12 /PRNewswire/ -- (Nasdaq: PRLN) Paracelsian, Inc. (http://www.paracelsian.com) announced today that Biomar International, Inc. has exercised its warrants for Paracelsian common stock in the aggregate amount of $520,000. The warrants were issued in connection with the initial investment transaction between Paracelsian and Biomar in January, 1998. "For an early stage company such as Biomar, capital is our most precious resource. Our initial investment in January put Biomar's survival at risk," said T. Nelson Campbell, Biomar's Chairman. "The extraordinary efforts of Bernie Landes, Paracelsian's CEO, and the rest of the administrative and science team at Paracelsian have validated our initial belief in the promise of Paracelsian. Our follow-up investment is a vote of confidence in this hardworking and talented team," Mr. Campbell added. In a related development, Paracelsian announced today that its Board of Directors has approved an extension of the warrants for Common Stock through September 6, 1999. The warrants, which were a dividend in September 1993, were set to expire on September 6, 1998. In addition to extension of the warrants, the Paracelsian Board of Directors approved changes to the exercise price of the warrants. The exercise price will be reduced from $3.25 to $1.75 through December 1998. The exercise price will increase to $2.50 from January 1, 1999 to April 30, 1999, and to $3.25 from May 1, 1999 to September 6, 1999. Holders of the warrants will be notified by mail and provided with the details of the changes. "We have made the adjustments to our publicly traded warrants as part of our overall financing strategy," said Bernie Landes, Paracelsian's President and CEO. "We anticipate that the exercise of warrants will help bridge the Company into positive cash flow from our relationship with R.P. Scherer and our other initiatives," he added. Paracelsian is a unique biotechnology company whose business centers on the development and application of functional bioassays. These assays are used for Quality Assurance of herbs, botanicals and other dietary supplements, in the development of dietary supplement, OTC and pharmaceutical products, and in monitoring environmental toxins and identifying carcinogens. This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects," "plans," "will," "estimates," "forecasts," "projects," or words of similar meaning. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. SOURCE Paracelsian, Inc. -0- 08/12/98 /CONTACT: Bernie Landes, President and CEO of